How Americans view weight-loss drugs and their potential impact on obesity in the U.S., Pew Research Center (2024) Obesity and depression: Its prevalence and influence as a prognostic factor: a systematic review, Psychiatry Investigation (2020) Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies, Archives of General Psychiatry (2010) Wellbutrin label, GlaxoSmithKline Serotonin syndrome, Cleveland Clinic (2022) Controlled substances, Drug Enforcement Administration Label: Phentermine hydrochloride tablet, DailyMed (2014) Bupropion (Wellbutrin), National Alliance on Mental Illness Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Use a new needle for each weekly dose
Compared with other GLP-1RAs, treatment with semaglutide or tirzepatide was not associated with risk of NAION (HR, 1.75 [95% CI, 0.98-3.10]) but was associated with increased risk of other optic nerve disorders (HR, 1.94 [95% CI, 1.32-2.85]) and other optical disc orders (HR, 1.39 [95% CI, 1.00-1.93]) (Figure 4)
It is important to note that compounded Semaglutide is not a magic bullet for weight loss
Diabetes Care 2008;31(8): 16791685
